Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab

Anne-Sofie Greve; Sivagini Prakash; Søren Krag; Else Randers

doi:10.1007/s40620-022-01504-9

Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab

Anne-Sofie Greve^*, Sivagini Prakash, Søren Krag, Else Randers

^*Corresponding author for this work

Department of Clinical Medicine - The Department of Pathology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.

Original language	English
Journal	Journal of Nephrology
Volume	36
Issue	3
Pages (from-to)	659-661
Number of pages	3
ISSN	1121-8428
DOIs	https://doi.org/10.1007/s40620-022-01504-9
Publication status	Published - Apr 2023

Keywords

Adult
Albuminuria/complications
Glomerulosclerosis, Focal Segmental/drug therapy
Humans
Male
Multiple Sclerosis/complications
Proteinuria/etiology
Young Adult

Access to Document

10.1007/s40620-022-01504-9

Cite this

@article{9e95897b741b4d50ac195334e0d3ccba,

title = "Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab",

abstract = "We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.",

keywords = "Adult, Albuminuria/complications, Glomerulosclerosis, Focal Segmental/drug therapy, Humans, Male, Multiple Sclerosis/complications, Proteinuria/etiology, Young Adult",

author = "Anne-Sofie Greve and Sivagini Prakash and S{\o}ren Krag and Else Randers",

year = "2023",

month = apr,

doi = "10.1007/s40620-022-01504-9",

language = "English",

volume = "36",

pages = "659--661",

journal = "Journal of Nephrology",

issn = "1121-8428",

publisher = "Springer",

number = "3",

}

Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab. / Greve, Anne-Sofie; Prakash, Sivagini; Krag, Søren et al.
In: Journal of Nephrology, Vol. 36, No. 3, 04.2023, p. 659-661.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab

AU - Greve, Anne-Sofie

AU - Prakash, Sivagini

AU - Krag, Søren

AU - Randers, Else

PY - 2023/4

Y1 - 2023/4

N2 - We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.

AB - We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.

KW - Adult

KW - Albuminuria/complications

KW - Glomerulosclerosis, Focal Segmental/drug therapy

KW - Humans

KW - Male

KW - Multiple Sclerosis/complications

KW - Proteinuria/etiology

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=85142225479&partnerID=8YFLogxK

U2 - 10.1007/s40620-022-01504-9

DO - 10.1007/s40620-022-01504-9

M3 - Journal article

C2 - 36414886

SN - 1121-8428

VL - 36

SP - 659

EP - 661

JO - Journal of Nephrology

JF - Journal of Nephrology

IS - 3

ER -

Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this